BIOTECHNOLOGY VALUE FUND II LP
CIK 1102444 · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.33B
Companies
20
Total Filings
46
Lifetime Open-Market Net
-$1.15B
Filer Profile
Reported Address
44 MONTGOMERY STREET40TH FL
SAN FRANCISCO, CA 94104
Phone
(312) 506-6500
State of Incorporation
DE
Related Filers
BIOTECHNOLOGY VALUE FUND L P — 509 joint filings, latest 2026-07-16
BVF INC/IL — 509 joint filings, latest 2026-07-16
BVF PARTNERS L P/IL — 509 joint filings, latest 2026-07-16
MARK N LAMPERT — 354 joint filings, latest 2026-07-16
BVF INVESTMENTS LLC — 259 joint filings, latest 2017-07-18
BVF Partners OS Ltd. — 237 joint filings, latest 2026-07-16
Biotechnology Value Trading Fund OS LP — 237 joint filings, latest 2026-07-16
BVF GP HOLDINGS LLC — 155 joint filings, latest 2026-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 1,671,048 | $114.96 | $192.10M | -$1.43B | 4 | 2026-06-26 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 62,383 | $15.70 | $979.4K | $0 | 1 | 2025-06-17 | |
| MLTX | Director | 10,235,089 | $12.51 | $128.04M | $0 | 1 | 2025-06-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,792,157 | $2.65 | $10.05M | $28.21M | 1 | 2023-11-03 | |
| RAIN | 1,479,460 | $0.74 | $1.09M | $21.20M | 3 | 2021-09-23 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 4,336,875 | $38.00 | $164.80M | $33.14M | 2 | 2020-10-08 | |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 1,948,819 | $40.17 | $78.28M | $21.66M | 6 | 2020-09-01 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 3,927 | $13.60 | $53.4K | -$1.57M | 1 | 2019-09-10 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,372,596 | $0.04 | $284.9K | $20.07M | 2 | 2018-11-21 |
| SNDX | 85,038 | $18.18 | $1.55M | $0 | 1 | 2018-06-20 | |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 1,898,293 | — | — | $3.08M | 4 | 2015-02-09 | |
| CCXI | 485,412 | $12.32 | $5.98M | $11.62M | 1 | 2013-09-13 | |
| NBIX | 756,600 | $156.22 | $118.20M | $2.48M | 1 | 2011-10-12 | |
| CAPS | 952 | $0.18 | $173 | $1.55M | 2 | 2011-08-22 | |
| Celera CORP (CRA) Delisted | 31,520,834 | — | — | $155.25M | 4 | 2011-05-10 | |
| AVIGEN INC \DE (AVGN) Delisted | 15,674,378 | — | — | -$5.6K | 1 | 2009-11-20 | |
| RPRX | 2,145,776 | $58.61 | $125.76M | -$3.60M | 1 | 2009-09-24 | |
| CRIS | 4,097 | $1.13 | $4.6K | -$17.08M | 1 | 2009-04-29 | |
| LGND | 10%+ Owner | 2,663,034 | $284.47 | $757.55M | $5.66M | 5 | 2009-01-27 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 8,135,099 | — | — | $773.0K | 1 | 2008-11-12 |
Recent Filings · Page 2 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-25 | RAIN | Buy (P) | +1,233,470 | $19.66M | EDGAR |
| 2021-04-27 | RAIN | Mixed | +49,286,040 | $191.03M | EDGAR |
| 2020-10-08 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +3,452,410 | $17.38M | EDGAR |
| 2020-09-01 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +356,210 | $6.66M | EDGAR |
| 2020-03-20 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +44,390 | $644.7K | EDGAR |
| 2019-10-08 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +4,210,374 | $15.76M | EDGAR |
| 2019-09-10 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Sell (S) | −350,000 | -$1.57M | EDGAR |
| 2018-12-04 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +68,600 | $1.02M | EDGAR |
| 2018-11-29 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +207,900 | $3.14M | EDGAR |
| 2018-11-21 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +10,288,782 | $14.08M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.